Clinical events leading to the progression of heart failure: insights from a national database of hospital discharges.

AIMS To describe the sequence of clinically apparent events causing readmission and antedating death, subsequent to a first-time hospital admission for heart failure, in order to give insights into the natural history and mechanisms of progression of heart failure. METHODS A national database of linked hospital discharge and mortality data for Scotland (population 5.1 million) was used. Patients with a first-time admission to hospital with heart failure in 1992 (index population) were identified and, using a record linkage system, hospital readmissions and their cause according to the hospital physician and deaths were recorded over the subsequent 3 years. A flowchart showing the sequence of events leading to death or recurrent admission was constructed. RESULTS 12 640 patients had first-time admissions with heart failure in 1992; their mean age was 74 years and 46.2% were men. A cohort of 2922 (23%) patients died on their first admission. Among the remaining 9718 patients there were 22 747 readmissions and 4877 deaths over the subsequent 3 years; only 15% had neither event reported. Nine per cent of patients died without any readmission and a further 6% without a further readmission for cardiovascular reasons. A cohort of 5992 (61% of patients at risk) had at least one cardiovascular readmission and half of these had occurred within 6 months. Heart failure without a report of any cardiovascular precipitating event was responsible for 37% (2188 patients) of first cardiovascular readmissions and of these patients approximately 12% had evidence of renal failure or acute respiratory infection as possible triggers for readmission. Acute ischaemic events including myocardial infarction (19%), myocardial infarction alone (8%) and atrial fibrillation (11%) were associated with a substantial number of first readmissions. First readmission precipitated by acute myocardial infarction was associated with a particularly poor prognosis (40% inpatient mortality). CONCLUSIONS Recurrent ischaemic events and atrial fibrillation may be the predominant mechanisms leading to exacerbation of and progression of heart failure and death. A substantial proportion of readmissions appear related to heart failure alone. Whether this reflects progressive ventricular remodelling leading to worsening heart failure or other unidentified mechanisms cannot be discerned from this data.

[1]  Therapy Study Investigators Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure , 1993, The Lancet.

[2]  G. Lamas,et al.  Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. , 1994, Circulation.

[3]  S G Thompson,et al.  Incidence and aetiology of heart failure; a population-based study. , 1999, European heart journal.

[4]  J. Cleland,et al.  Sudden death in heart failure: vascular or electrical? , 1999, European journal of heart failure.

[5]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[6]  J. Cleland,et al.  Systematic review of the management of atrial fibrillation in patients with heart failure. , 2000, European heart journal.

[7]  Y Wang,et al.  Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. , 1997, Archives of internal medicine.

[8]  Annual Report of the Registrar-General , 1857, Journal of public health, and sanitary review.

[9]  R. Cooper,et al.  Precipitating factors leading to decompensation of heart failure. Traits among urban blacks. , 1988, Archives of internal medicine.

[10]  L. Tavazzi,et al.  Concomitant factors of decompensation in chronic heart failure. , 1996, The American journal of cardiology.

[11]  CIBIS-II Investigators and Committees The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[12]  J. McMurray,et al.  Importance of heart failure as a cause of death. Changing contribution to overall mortality and coronary heart disease mortality in Scotland 1979-1992. , 1998, European heart journal.

[13]  R. Falk,et al.  The WASH study (warfarin/aspirin study in heart failure) rationale, design and end-points , 1999 .

[14]  A. Michalsen,et al.  Preventable causative factors leading to hospital admission with decompensated heart failure , 1998, Heart.

[15]  B. Pitt,et al.  Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions , 1992, The Lancet.

[16]  M. Rich,et al.  Early Readmission of Elderly Patients With Congestive Heart Failure , 1990, Journal of the American Geriatrics Society.

[17]  Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. The West of Scotland Coronary Prevention Study Group. , 1995, Journal of clinical epidemiology.

[18]  R. Patten,et al.  Ventricular remodeling and its prevention in the treatment of heart failure. , 1998, Current opinion in cardiology.

[19]  T. Inoue,et al.  Heart failure progression due to secondary organ dysfunction in acute heart failure. , 1995, Japanese heart journal.

[20]  L. Rydén,et al.  Improved knowledge of antidiabetic treatment--a necessity for the modern cardiologist. , 1999, European heart journal.

[21]  P C Deedwania,et al.  Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. , 1998, Circulation.

[22]  Great Britain. Foreign Office.,et al.  Forty-Fifth Annual Report of the Registrar-General for Scotland , 1900 .

[23]  G. Murray,et al.  Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators , 1993 .

[24]  D E Grobbee,et al.  The epidemiology of heart failure. , 1997, European heart journal.

[25]  M. Pfeffer,et al.  Effect of left ventricular sphericity on the evolution of ventricular dysfunction in rats with diffuse isoproterenol-induced myocardial necrosis. , 1998, Journal of cardiac failure.

[26]  J. McMurray,et al.  Trends in hospitalization for heart failure in Scotland 1980-1990. , 1993, European heart journal.

[27]  How accurate are SMR1 (Scottish Morbidity Record 1) data? , 1992, Health bulletin.

[28]  G. Bonsel,et al.  UvA-DARE ( Digital Academic Repository ) Cardiovascular disease in the Netherlands , 1975 to 1995 : decline in mortality , but increasing numbers of patients with chronic conditions , 1999 .

[29]  A. Patel,et al.  Scottish hospital morbidity data. 1. Errors in diagnostic returns. , 1976, Health bulletin.

[30]  Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. , 1995, Circulation.

[31]  L. Køber,et al.  Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. , 1999, Circulation.

[32]  S. Kendrick,et al.  The Scottish Record Linkage System. , 1993, Health bulletin.

[33]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[34]  Knill-Jones Rp,et al.  How accurate are SMR1 (Scottish Morbidity Record 1) data , 1992 .

[35]  A. Jette,et al.  Hospital Readmissions Among the Elderly , 1985, Journal of the American Geriatrics Society.

[36]  A. Hoes,et al.  Prevention of relapse in patients with congestive heart failure: the role of precipitating factors , 1998, Heart.

[37]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[38]  S. Yusuf,et al.  Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. , 1994, Circulation.

[39]  K Harley,et al.  Quality of Scottish Morbidity Record (SMR) data. , 1996, Health bulletin.

[40]  F. Tristani,et al.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.

[41]  P. Lechat Prevention of heart failure progression: current approaches. , 1998, European heart journal.

[42]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[43]  J. Croft,et al.  Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. , 1999, American heart journal.

[44]  D. Levy,et al.  The epidemiology of heart failure: the Framingham Study. , 1993, Journal of the American College of Cardiology.

[45]  G. Lamas,et al.  Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. , 1997, Circulation.

[46]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[47]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[48]  J. Cleland,et al.  Is the prognosis of heart failure improving? , 1999, Journal of the American College of Cardiology.

[49]  M. Komajda,et al.  Risk stratification in chronic heart failure. , 1998, European heart journal.

[50]  E J Topol,et al.  Cause of death in clinical research: time for a reassessment? , 1999, Journal of the American College of Cardiology.

[51]  I. V. Van Gelder,et al.  Heart failure and atrial fibrillation: current concepts and controversies. , 1997, Heart.

[52]  T. Ogihara,et al.  Reduction of risk of pneumonia associated with use of angiotensin I converting enzyme inhibitors in elderly inpatients. , 1999, American journal of hypertension.

[53]  W. Remme Prevention of worsening heart failure: future focus. , 1998, European heart journal.

[54]  A. Hall,et al.  Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. , 1997, European heart journal.

[55]  L. Køber,et al.  Angiotensin-converting enzyme inhibition after myocardial infarction: the Trandolapril Cardiac Evaluation Study. , 1996, American heart journal.

[56]  N. Bayley,et al.  Failure , 1890, The Hospital.

[57]  A. Hall,et al.  Mode of death in chronic heart failure. A request and proposition for more accurate classification. , 1996, European heart journal.

[58]  Dwight Lemon,et al.  Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1 , 1987 .